Unlocking the Potential of PEBP4 as a Drug Target and Biomarker

Target Name: PEBP4

NCBI ID: G157310

PEBP4

Unlocking the Potential of PEBP4 as a Drug Target and Biomarker

Introduction

Phosphatidylethanolamine (PE)AM is a type of phospholipid that plays a crucial role in various biological processes, including cell signaling, inflammation, and memory. PEBP4, a protein that belongs to the family of phospholipase C family 4 (PLC4), has been identified as a potential drug target and biomarker for various diseases. In this article, we will explore the structure, function, and potential therapeutic applications of PEBP4.

Structure and Function

PEBP4 is a 120-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is composed of two N-terminal alpha-helices and a C-terminal region that contains a unique N-terminal hypervariable region (HVR). The HVR is responsible forPEBP4's unique localization and stability in various cellular compartments.

PEBP4 functions as a negative regulator of the phosphatidylcholine (PC) synthesis pathway, which is a critical pathway for the synthesis of the major phospholipid, PC, in cell membranes. This pathway is also known as the \"Choline Synthesis Network\" (CSN). The CSN consists of multiple enzymes, including PEBP4, that are involved in the production of PC.

During the cell signaling process, PEBP4 plays a crucial role in the regulation of various signaling pathways, including the production of neurotransmitters, such as dopamine and serotonin. By regulating the levels of PC, PEBP4 enables the cell to maintain the appropriate balance of different phospholipids , which are essential for maintaining membrane structure and function.

In addition to its role in cell signaling, PEBP4 is also a potent biomarker for various diseases. The levels of PEBP4 have been shown to be reduced in various disease-related tissues, including cancer, neurodegenerative diseases, and cardiovascular diseases. This suggests that PEBP4 may serve as a promising biomarker for these diseases.

Potential Therapeutic Applications

The therapeutic potential applications of PEBP4 are vast and varied. As a negative regulator of the PC synthesis pathway, PEBP4 may have a therapeutic impact on various diseases that are caused by disruptions in the production of PC. Some potential therapeutic applications of PEBP4 are:

1.Cancer

Cancer is a leading cause of death worldwide, and its development is often associated with the production of excess PC. PEBP4 has been shown to play a negative role in the regulation of PC synthesis in various cancer cells. For example, studies have shown that PEBP4 is downregulated in various cancer tissues, including breast, ovarian, and colorectal cancer. Therefore, targeting PEBP4 with drugs that can promote its expression could be a promising strategy for cancer treatment.

2. Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These diseases are often associated with the production of excess PC and disruptions in the production of memory and learning disorders.

PEBP4 has been shown to be involved in the regulation of PC synthesis in various neurodegenerative tissues. For example, studies have shown that PEBP4 is downregulated in the brain, and its levels have been associated with the progression of neurodegenerative diseases. Therefore, targeting PEBP4 with drugs that can promote its expression could be a promising strategy for the treatment of neurodegenerative diseases.

3. Cardiovascular Diseases

Cardiovascular diseases, such as heart failure, hypertension, and stroke, are characterized by the development of blood clots and the blockage of blood vessels. These diseases are often associated with the production of excess PC and disruptions in the production of cardiovascular signaling molecules.

PEBP4 has been shown to play a negative role in the regulation of PC synthesis in various cardiovascular tissues. For example, studies have shown that PEBP4 is downregulated in the heart and is associated with the development of cardiovascular disease. Therefore, targeting PEBP4 with drugs that can promote its expression could be a promising strategy for the treatment of cardiovascular diseases.

Conclusion

PEBP4 is a protein that has

Protein Name: Phosphatidylethanolamine Binding Protein 4

Functions: Promotes AKT phosphorylation, suggesting a possible role in the PI3K-AKT signaling pathway

The "PEBP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEBP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets